A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Esophageal Squamous Cell Carcinoma (ESCC) Failed or Intolerance to Standard First-line Therapy
Latest Information Update: 12 Feb 2025
Price :
$35 *
At a glance
- Drugs HLX 43 (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 10 Feb 2025 According to Shanghai Henlius Biotech media release, Status changed from not yet recruiting to recruiting.
- 10 Feb 2025 According to Shanghai Henlius Biotech media release, company announced that the first subject has been dosed for this trial.
- 16 Jan 2025 New trial record